Sale of Equity Interests in Theravance Respiratory Company, LLS and Discontinued Operations - Summary of TRC's statement of income and equity Interest (Details) - USD ($) $ in Thousands	3 Months Ended								7 Months Ended	12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jul. 20, 2022	Dec. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 39,545				$ 298,172					$ 39,545	$ 298,172
Total assets	381,999				607,400					381,999	607,400
Liabilities and LLC Members' Equity
Total liabilities and shareholders' equity	381,999				607,400					381,999	607,400
Revenue:
Total revenue	$ 17,565	$ 15,693	$ 13,749	$ 10,417	$ 14,649	$ 12,451	$ 11,050	$ 13,196		57,424	51,346
Collaboration revenue
Revenue:
Total revenue										$ 216	$ 192
TRC
Assets
Total assets									$ 72,029
Liabilities and LLC Members' Equity
Total liabilities and shareholders' equity									72,029
Revenue:
Total revenue									72,029
General and administrative expenses									(332)
Other income, net									10
Realized loss on equity and long-term investments									(39,385)
Changes in fair value of equity and long-term investments, net									(8,884)
Net Income									23,438
TRC | TRC
Assets
Cash and cash equivalents									29,309
Related party receivables from collaborative arrangements									42,720
Liabilities and LLC Members' Equity
LLC members' equity									$ 72,029